CSIMarket Company Name, Ticker, Industry, else..
 
Pharmacyte Biotech Inc   (NASDAQ: PMCB)
 
Price: $0.4423 $-0.03 -6.943%
Day's High: $0.4999000132083893 Week Perf: -9.97 %
Day's Low: $ 0.43 30 Day Perf: -19.58 %
Volume (M): 112,797 52 Wk High: $ 1.51
Volume (M$): $ 0 52 Wk Avg: $0.77
Open: $0.48 52 Wk Low: $0.43



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 8
 Employees 2
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0

Business Description


Pharmacyte Biotech Inc. is a biotechnology company that focuses on developing medical treatments for cancer and diabetes. They are known for their innovative technology called Cell-in-a-Box, which involves encapsulating living cells in a protective coating. This technology allows for the targeted delivery of therapeutic cells to specific areas of the body, potentially offering more effective treatment options. Pharmacyte Biotech Inc. is committed to improving the lives of patients by developing novel therapies that have the potential to combat these devastating diseases.


   Company Address: 3960 Howard Hughes Parkway Las Vegas 89169 NV
   Company Phone Number: 595-2850   Stock Exchange / Ticker: NASDAQ PMCB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
APTO   -51%    
ENTX   -4.45%    
INAB      0% 
VIR   -8.17%    
VXRT        1.78% 
CNBK        1.78% 
• View Complete Report
   



Business Update

PharmaCyte Biotech Joins Forces with MyMD Pharmaceuticals with a $7 Million Investment to Revolutionize Inflammatory Disease Therapies

Published Tue, May 21 2024 1:51 PM UTC

PharmaCyte Biotech Invests $7 Million in MyMD Pharmaceuticals to Develop Novel Therapies for Inflammatory DiseasesPharmaCyte Biotech, a renowned biotechnology company specializing in cellular therapies for various diseases, has made a strategic investment of $7 million in MyMD Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing age-related disea...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.11
PEG (TTM) -

Financial Strength Current
Quick Ratio 6.76
Working Capital Ratio 6.88
Leverage Ratio (MRQ) 0.35
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.34 $
Revenues (TTM) -
Cash Flow (TTM) 0.6 $
Cash 2.25 $
Book Value 3.97 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -9,809,876
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.